$193.67
+0.26%Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Chairman, Chief Executive Officer & President
Compensation
$3,321,508
Executive Vice President & Chief Financial Officer
Compensation
$1,340,233
Executive Vice President of Regional Businesses
Compensation
$1,142,487
Senior Vice President & Chief Compliance Officer
Senior Vice President & General Counsel
Compensation
$967,084
Senior Vice President and Chief Information & Digital Officer
Senior Vice President and Chief Marketing & Communications Officer
Senior Vice President of Clinical Solutions
Compensation
$962,292
Senior Vice President, Corporate Controller & Chief Accounting Officer
Vice President of Investor Relations
During the last 12 months, insiders have sold $23.56M worth of DGX shares, with no buying activity reported.
0
0.00
10.0K
1.94M
-1.9M
-$1.94M
0
0.00
46.2K
9.57M
-9.6M
-$9.57M
0
0.00
47.4K
8.90M
-8.9M
-$8.90M
0
0.00
17.9K
3.15M
-3.1M
-$3.15M
No buying activity
Prevoznik Michael E
Officer: Svp & General Counsel
$6.49M
Davis J. E.
Director, Officer: Ceo And President
$5.86M
Plewman Patrick
Officer: Svp For Diagnostic Services
$3.92M
Doherty Catherine T.
Officer: Evp, Regional Businesses
$3.74M
Kuppusamy Karthik
Officer: Svp, Clinical Solutions
$1.79M
Strong bearish signal with $23.56M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
DGX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 04, 2025 | May 15, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 05, 2024 | May 16, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 06, 2023 | April 06, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 19, 2022 | May 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 09, 2021 | May 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 08, 2020 | May 19, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 03, 2019 | May 14, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 04, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 05, 2017 | May 16, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.